Efficacy and safety of sequential hyperthermic intraperitoneal chemotherapy following surgery for pathological T staging 4 gastric cancer

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 6

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastroenterol. Feb 14, 2026; 32(6): 115556
Published online Feb 14, 2026. doi: 10.3748/wjg.v32.i6.115556

Table 2 Chemotherapy agents for hyperthermic intraperitoneal chemotherapy and adjuvant chemotherapy regimen, n (%)

	HIPEC + AC group (n = 96)	AC group (n = 129)
Chemotherapy agents for HIPEC
Docetaxel	83 (86.46)	-
5-fluorouracil	13 (13.54)	-
AC regimen
Platinum-based agents	40 (41.67)	64 (49.61)
Taxanes	22 (22.92)	50 (38.76)
Platinum-taxane combinations	26 (27.08)	6 (4.65)
Camptothecins	8 (8.33)	9 (6.98)

AC: Adjuvant chemotherapy; HIPEC: Hyperthermic intraperitoneal chemotherapy.

Citation: Lian WL, Cai LS, Lian MQ, Lian MJ, Sun YQ, Lv CB, Huang GP, Huang RJ, Zhang YB, Zeng WM, Xu QH, Zhu QJ, Chen QX. Efficacy and safety of sequential hyperthermic intraperitoneal chemotherapy following surgery for pathological T staging 4 gastric cancer. World J Gastroenterol 2026; 32(6): 115556
URL: https://www.wjgnet.com/1007-9327/full/v32/i6/115556.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i6.115556

Lian WL, Cai LS, Lian MQ, Lian MJ, Sun YQ, Lv CB, Huang GP, Huang RJ, Zhang YB, Zeng WM, Xu QH, Zhu QJ, Chen QX. Efficacy and safety of sequential hyperthermic intraperitoneal chemotherapy following surgery for pathological T staging 4 gastric cancer. World J Gastroenterol 2026; 32(6): 115556 [PMID: 41695288 DOI: 10.3748/wjg.v32.i6.115556]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.